ADGI - Adagio Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology) Projected Earnings Date: 0000-02-29    (Delayed quote data   )
Last
 		 Change
 ⇓ 0.00   (%)		 Volume
  0
Open
 		 High
 		 Low
 
8EMA (Daily)
 0.00		 40EMA (Daily)
 		 50EMA (Daily)
 		 STO (Daily)
 		 MACD Hist (Daily)
 
8EMA (Weekly)
 4.370		 40EMA (Weekly)
 6.33		 50EMA (Weekly)
 6.88		 STO (Weekly)
 87.218		 MACD Hist (Weekly)
 0.849
Company Profile
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com